Highlights for January 2018

  1. Recipharm acquires remaining shares in Nitin Lifesciences Ltd worth $44 Million.
  2. Ipca Labs acquires US drugmaker Pisgah for $9.65 Million.
  3. Sandoz signed a global partnership with Indian drugmaker Biocon to develop, manufacture and commercialize multiple biosimilars in immunology and oncology.
  4. Torrent Pharmaceuticals acquired US-based generic pharmaceuticals and OTC firm Bio-Pharm Inc for an undisclosed amount.
  5. Novartis bought rights to Spark Therapeutic’s gene therapy for a certain type of vision loss, in a deal worth up to $170 million.
  6. Biogen bags Karyopharm neurological drug in $217M deal.
  7. Arvinas in $830M-plus Pfizer biobucks deal.
  8. Roche collaborates with MacroGenics in $380M DART deal.
  9. Aslan Pharmaceuticals acquired full commercial rights for Varlitinib from USA-based Array BioPharma in a deal worth $129 million.
  10. Takeda and Denali therapeutics collaborate to develop and commercialize therapies for Neurodegenerative Diseases for $150M upfront payment.
  11. Karyopharm Therapeutics sells ALS candidate to Biogen for up to $217 million.
  12. Exelixis collaborates with StemSynergy for novel anticancer therapies and pays $3 million as an upfront payment.

Updates at Aagami:

  • Aagami concluded a fruitful JPM week in San Francisco with more than 40 one-to-one partnering meetings.
  • Aagami CEO starts his business trip to South Korea, Japan and India (Jan 25-Feb27).